ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study

Liang, Yanrui*; Zhao, Liying; Chen, Hao; Lin, Tian; Chen, Tao; Zhao, Mingli; Hu, Yanfeng; Yu, Jiang; Liu, Hao; Li, Guoxin南方医科大学
BMC CANCER2021-2-25DOI: 10.1186/s12885-021-07919-0
10被引10阅读
引用收藏
分享

摘要

BackgroundThe benefits of adjuvant chemotherapy for elderly patients with gastric cancer (GC) remain unknown because elderly patients are underrepresented in most clinical trials. This study aimed to evaluate the effectiveness and complications of adjuvant chemotherapy in patients >65years of age after laparoscopic D2 gastrectomy.MethodsThis was a single-center retrospective cohort study of elderly patients (>65years) with stage II/III GC who underwent curative laparoscopic D2 gastrectomy with R0 resection between 2004 and 2018. The adjuvant chemotherapy regimens included monotherapy (oral capecitabine) and doublet chemotherapy (oral capecitabine plus intravenous oxaliplatin [XELOX] or intravenous oxaliplatin, leucovorin, and 5-fluorouracil [FOLFOX]). The data were retrieved from a prospectively registered database maintained at the Department of General Surgery in Nanfang Hospital, China. The patients were divided as surgery alone and surgery plus adjuvant chemotherapy (chemo group). The overall survival (OS), disease-free survival (DFS), chemotherapy duration, and toxicity were examined.ResultsThere were 270 patients included: 169 and 101 in the surgery and chemo groups, respectively. There were 10 (10/101) and six (6/101) patients with grade 3+ non-hematological and hematological adverse events. The 1-/3-/5-year OS rates of the surgery group were 72.9%/51.8%/48.3%, compared with 90.1%/66.4%/48.6% for the chemo group (log-rank test: P =0.018). For stage III patients, the 1-/3-/5-year OS rates of the surgery group were 83.7%/40.7%/28.7%, compared with 89.9%/61.2%/43.6% for the chemo group (log-rank test: P =0.015). Adjuvant chemotherapy was significantly associated with higher OS (HR=0.568, 95%CI: 0.357-0.903, P =0.017) and DFS (HR=0.511, 95%CI: 0.322-0.811, P =0.004) in stage III patients.ConclusionsThis study suggested that adjuvant chemotherapy significantly improves OS and DFS compared with surgery alone in elderly patients with stage III GC after D2 laparoscopic gastrectomy, with a tolerable adverse event profile.

学科与关键词

关键词
Gastric cancerGastrectomyAdjuvant chemotherapyOverall survival
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2021-02-25
卷期
第 21 卷, 第 1 期
页码
196
DOI
10.1186/s12885-021-07919-0
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
State's Key Project of Research and Development Plan [2017YFC0108300]; National Natural Science Foundation of China [81672446]; Southern Medical University Clinical Research Start-Up Project [LC2016ZD003]; Key Clinical Specialty Discipline Construction Program [[2012]121]

作者

  • L

    Liang, Yanrui (通讯) (第一作者)

    southern med univ

  • Z

    Zhao, Liying

    southern med univ

查看全部 10 位作者收起作者
  • C

    Chen, Hao

    southern med univ

  • L

    Lin, Tian

    southern med univ

  • C

    Chen, Tao

    southern med univ

  • Z

    Zhao, Mingli

    southern med univ

  • H

    Hu, Yanfeng

    southern med univ

  • Y

    Yu, Jiang

    southern med univ

  • L

    Liu, Hao

    southern med univ

  • L

    Li, Guoxin

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417